Probiotics industry: review of current challenges and the future roadmap - Payesh (Health Monitor)
Wed, May 22, 2024
Volume 20, Issue 3 (May - June 2021)                   Payesh 2021, 20(3): 263-273 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Damari ‌, Tajabadi Ebrahimi M, Jafarvand E. Probiotics industry: review of current challenges and the future roadmap. Payesh 2021; 20 (3) :263-273
1- Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
2- Central Tehran Branch, Islamic Azad University, Tehran, Iran
3- School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
Abstract:   (2495 Views)
Objective (s): Deaths from non-communicable diseases have become a major concern worldwide. Functional foods such as probiotics, prebiotics and synbiotics are effective nutritional factors in controlling non-communicable diseases. The purpose of this study was to review and organize the existing situation and design the future roadmap.
Methods: The present study was a qualitative study that conducted by the Society of Probiotic and Functional Foods in collaboration with the National Institute of Health Research of the Islamic Republic of Iran in 2015. The policy brief was used in design and was formulated in three parts: cognition, orientation, and establishment of system. The information was collected through three methods of scientific resource review, stakeholder focus group discussion and written questionnaire. Data were analyzed using content analysis method.
Results: The number of probiotic factories was 85 and 163 probiotic products had received production licenses in the country. The annual growth of the probiotic market from 2009 to 2014 was negative (54%). The policy focus areas for the development of probiotics and functional foods were distributed in three areas: legal policy, behavioral culture and operational structure and the development of this industry depends on planning and implementation in all three areas.
Conclusion: To develop the probiotic industry it is necessary to increase the knowledge of policy makers and consumer groups about probiotic products. Indeed, investment security in this area be provided and a system be deployed to monitor the development of the industry and solve its problems.
Full-Text [PDF 762 kb]   (1898 Downloads)    
type of study: Descriptive | Subject: Public Health
Received: 2021/01/8 | Accepted: 2021/06/23 | ePublished ahead of print: 2021/07/3 | Published: 2021/07/3

1. Azadnajafabad S, Mohammadi E, Aminorroaya A, Fattahi N, Rezaei S, Haghshenas R, et al. Non-communicable diseases' risk factors in Iran; a review of the present status and action plans. Journal of Diabetes and Metabolic Disorders 2021;22:1-9 [DOI:10.1007/s40200-020-00709-8]
2. Institute for Health Metrics and Evaluation (IHME). Global Health Data exchange (GHDx) 2019. Available on: [Accessed 21 Apr 2021]
3. Khosravi Shadmani F, Farzadfar F, Larijani B, Mirzaei M, Haghdoost AA. Trend and projection of mortality rate due to non-communicable diseases in Iran: A modeling study. PloS one 2019;14:e0211622. [DOI:10.1371/journal.pone.0211622]
4. Aminorroaya A, Fattahi N, Azadnajafabad S, Mohammadi E, Jamshidi K, Khalilabad MR, et al. Burden of non-communicable diseases in Iran: past, present, and future. Journal of Diabetes and Metabolic Disorders 2020;19:1-7 [DOI:10.1007/s40200-020-00669-z]
5. Low W-Y, Lee Y-K, Samy AL. Non-communicable diseases in the Asia-Pacific region: Prevalence, risk factors and community-based prevention. International Journal of Occupational Medicine and Environmental Health 2015;28:20-6 [DOI:10.2478/s13382-014-0326-0]
6. Peykari N, Hashemi H, Dinarvand R, Haji-Aghajani M, Malekzadeh R, Sadrolsadat A, et al. National action plan for non-communicable diseases prevention and control in Iran; a response to emerging epidemic. Journal of Diabetes and Metabolic Disorders 2017;16:3 [DOI:10.1186/s40200-017-0288-4]
7. Di Daniele N. The Role of Preventive Nutrition in Chronic Non-Communicable Diseases. Nutrients 2019;11:1074 [DOI:10.3390/nu11051074]
8. Noce A, Marrone G, Di Daniele F, Ottaviani E, Wilson Jones G, Bernini R, et al. Impact of Gut Microbiota Composition on Onset and Progression of Chronic Non-Communicable Diseases. Nutrients 2019;11:1073 [DOI:10.3390/nu11051073]
9. Fuller R. Probiotics in man and animals. Journal of Applied Microbiology 1989;66:365-78 [DOI:10.1111/j.1365-2672.1989.tb05105.x]
10. Food and Agriculture Organization, World Health Organization. Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food, London, Ontario, Canada 2002:1:1-11
11. Sun‐Waterhouse D. The development of fruit‐based functional foods targeting the health and wellness market: a review. International Journal of Food Science and Technology 2011;46:899-920 [DOI:10.1111/j.1365-2621.2010.02499.x]
12. Pandey KR, Naik SR, Vakil BV. Probiotics, prebiotics and synbiotics-a review. International Journal of Food Science & Technology 2015;52:7577-87 [DOI:10.1007/s13197-015-1921-1]
13. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nature Reviews Genetics 2012;13:260-70 [DOI:10.1038/nrg3182]
14. Dror T, Dickstein Y, Dubourg G, Paul M. Microbiota manipulation for weight change. Microbial Pathogenesis 2017;106:146-61 [DOI:10.1016/j.micpath.2016.01.002]
15. Razmpoosh E, Javadi M, Ejtahed HS, Mirmiran P. Probiotics as beneficial agents in the management of diabetes mellitus: a systematic review. Diabetes/Metabolism Research and Reviews 2016;32:143-68 [DOI:10.1002/dmrr.2665]
16. Beserra BT, Fernandes R, do Rosario VA, Mocellin MC, Kuntz MG, Trindade EB. A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity. Clinical Nutrition 2015;34:845-58 [DOI:10.1016/j.clnu.2014.10.004]
17. Hibberd AA, Lyra A, Ouwehand AC, Rolny P, Lindegren H, Cedgard L, et al. Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. BMJ Open Gastroenterology 2017;4:e000145 [DOI:10.1136/bmjgast-2017-000145]
18. Bazhan M, Kalantari N, Keshavarz-Mohammadi N. Health-enhancing foods: barriers to consumers' choice in Iran. Health Promotion International. 2020; Avaialable on: [DOI:10.1093/heapro/daaa088 [Accessed Apr 2021].]
19. Metchnikoff II. The prolongation of life: optimistic studies. 1st EditionOutlook Verlag GmbH: Germany, 2004
20. Sanders ME. Development of consumer probiotics for the US market. British Journal of Nutrition 1998;80:213-8 [DOI:10.1017/S000711450000605X]
21. Nazir M, Arif S, Khan RS, Nazir W, Khalid N, Maqsood S. Opportunities and Challenges for Functional and Medicinal Beverages: Current and Future Trends. Trends in Food Science and Technology 2019;88:518-26 [DOI:10.1016/j.tifs.2019.04.011]
22. Temesi A, Bacso A, Grunert KG, Lakner Z. Perceived correspondence of health effects as a new determinant influencing purchase intention for functional food. Nutrients 2019;11:740 [DOI:10.3390/nu11040740]
23. Annunziata A, Vecchio R, Kraus A. Factors affecting parents' choices of functional foods targeted for children. International Journal of Consumer Studies 2016;40:527-35 [DOI:10.1111/ijcs.12297]
24. Daliri EB-M, Lee BH. Current trends and future perspectives on functional foods and nutraceuticals. Beneficial microorganisms in food and nutraceuticals 2015;27:221-44 [DOI:10.1007/978-3-319-23177-8_10]
25. Sorenson D, Bogue J. Consumer-oriented development of functional beverages. Functional and Speciality Beverage Technology 2009;3:421-50 [DOI:10.1533/9781845695569.4.421]

Add your comments about this article : Your username or Email:

Rights and Permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Payesh (Health Monitor)

Designed & Developed by : Yektaweb